Interim report 2026
Filed with HKEX · Stock code 2696 · · 90 pages · English
Summary by 6ix AI
The report highlights significant growth in total revenue, driven by increased drug sales and research services. Additionally, the company has expanded its product approvals and international market presence, with multiple products now available in various countries. The report also outlines ongoing research and development efforts aimed at innovative treatments for complex diseases.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Shanghai Henlius Biotech, Inc. on 6ix
Earlier from Shanghai Henlius Biotech
- Voluntary announcement - collaboration and license agreement with amberstone for two T Cell Engager products
- Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation
- Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
- Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
- FDA Approves Shanghai Henlius Biotech IND For Cetuximab Biosimilar
Later from Shanghai Henlius Biotech
- (1) Changes in non-executive director and independent non-executive director (2) appointment of chairman of the board and changes in composition of the board committees
- List of directors and their roles and functions
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Continuing connected transaction - revision of annual cap for the collaboration arrangements under the HLX01 agreement
- (1) Continuing connected transaction revision of annual cap for the collaboration arrangements under the HLX01 agreement (2) proposed appointment of non-executive director and independent non-executive director and notice of extraordinary general meeting
Follow Shanghai Henlius Biotech into a list and get an email when it puts out news.
Follow Shanghai Henlius Biotech